New Clinical Trial Results Reported for Pulmonary Embolism and Atrial Fibrillation Devices

Boston Scientific has presented new clinical data that may reshape interventional approaches to both pulmonary embolism (PE) and stroke prevention in atrial fibrillation (AF), according to findings highlighted during a recent American College of Cardiology (ACC) conference call.

Company executives pointed to results from two randomized clinical trials, characterizing the outcomes as potentially “practice transforming” for these high-risk cardiovascular conditions.

One of the trials, HI-PEITHO, evaluated the company’s EKOS™ Endovascular System in patients with acute pulmonary embolism. The study demonstrated that the device was superior to standard of care, suggesting a potential shift in how clinicians manage this life-threatening condition. Pulmonary embolism, which involves obstruction of pulmonary arteries by thrombus, remains a major cause of cardiovascular morbidity and mortality, and advances in catheter-directed therapies have been closely watched as alternatives to systemic thrombolysis.

The second study, CHAMPION-AF, focused on stroke prevention in patients with atrial fibrillation. This trial assessed the WATCHMAN FLX™ Left Atrial Appendage Closure device as a first-line therapy and reported that it met all primary and secondary safety and efficacy endpoints. The findings suggest that device-based left atrial appendage closure could be considered earlier in the treatment pathway, rather than being reserved primarily for patients who are unsuitable for long-term anticoagulation.

Together, the results reflect a broader trend toward device-driven interventions in cardiovascular care, particularly in areas where pharmacologic therapy has traditionally dominated. In AF, oral anticoagulants have long been the standard for stroke prevention, but limitations such as bleeding risk and adherence challenges have fueled interest in mechanical alternatives. Similarly, in PE, catheter-based strategies are being explored to improve outcomes while potentially reducing complications associated with systemic therapies.

Boston Scientific emphasized that both studies were randomized trials, a design considered the gold standard for evaluating clinical efficacy. The company’s description of the data as “practice transforming” underscores the degree to which these findings may influence clinical guidelines and physician decision-making if adopted more widely.

The announcement also highlights the increasing role of large-scale clinical evidence in supporting adoption of medical devices. As device technologies evolve, demonstrating not only safety but also superiority over established standards of care is becoming essential for integration into routine practice.

While the full implications of these trials will depend on peer-reviewed publication and guideline review, the data presented at ACC position both the EKOS™ system and WATCHMAN FLX™ device as potentially important tools in the management of thromboembolic disease. For clinicians, the findings may signal an inflection point in how interventional strategies are incorporated into care pathways for both pulmonary embolism and atrial fibrillation.